Clinical significance of serum expression of GROβ in esophageal squamous cell carcinoma

World J Gastroenterol. 2011 Jun 7;17(21):2658-62. doi: 10.3748/wjg.v17.i21.2658.

Abstract

Aim: To determine the association between serum levels of growth-related gene product β (GROβ) and clinical parameters in esophageal squamous cell carcinoma (ESCC).

Methods: Using enzyme-linked immunosorbent assay, serum GROβ levels were measured in ESCC patients (n = 72) and healthy volunteers (n = 83). The association between serum levels of GROβ and clinical parameters of ESCC was analyzed statistically.

Results: The serum GROβ levels were much higher in ESCC patients than in healthy controls (median: 645 ng/L vs 269 ng/L, P < 0.05). Serum GROβ levels were correlated positively with tumor size, lymph node metastasis, and tumor-node-metastasis (TNM) staging, but not with gender or the histological grade of tumors in ESCC patients. The sensitivity and specificity of the assay for serum GROβ were 73.61% and 56.63%, respectively.

Conclusion: GROβ may function as an oncogene product and contribute to tumorigenesis and metastasis of ESCC.

Keywords: Cytokine; Esophageal squamous cell carcinoma; GROβ; Metastasis; Tumor markers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Carcinoma, Squamous Cell / blood*
  • Carcinoma, Squamous Cell / pathology
  • Chemokine CXCL2 / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Esophageal Neoplasms / blood*
  • Esophageal Neoplasms / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Oncogenes
  • Sensitivity and Specificity

Substances

  • Biomarkers, Tumor
  • CXCL2 protein, human
  • Chemokine CXCL2